Latest Vitra Bioscience News
Jan 6, 2017
Nov 28, 2005 Premium Vitra Bioscience, which commercially launched its flagship CellCard multiplexed cell-based assay system at the beginning of this year, has closed its doors and is currently seeking potential suitors to acquire all of the company's assets, according to two former Vitra officials. Ilya Ravkin, the company's co-founder and chief technology officer, told CBA News at IBC's High-Content Analysis conference held earlier this month in Washington, DC, that Vitra has "shut down" operations. Get the full story with GenomeWeb Premium Only $95 for the first 90 days* A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.